Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Additionally, the company announced an exclusive $1.8 billion license agreement with The United Laboratories for UBT251, a triple receptor agonist targeting GLP-1, GIP, and glucagon. The company also ...

BMO maintains Novo Nordisk stock Outperform rating, $105 target ...